Sangamo publishes corporate presentation highlighting neurology genomic medicines pipeline, Fabry BLA progress

Reuters03-31

Sangamo publishes corporate presentation highlighting neurology genomic medicines pipeline, Fabry BLA progress

Sangamo repositioned strategy around neurology-focused genomic medicines built on zinc-finger epigenetic regulation cargo, supported by STAC-BBB CNS delivery platform.
Chronic neuropathic pain candidate ST-503 entered Phase 1/2 STAND study in small fiber neuropathy; U.S. FDA granted Fast Track designation.
Prion disease program ST-506 advanced CTA-enabling work; GLP toxicology study completed with analysis ongoing.
Fabry gene therapy ST-920 moved through rolling BLA submission under Accelerated Approval; completion targeted as early as summer 2026 subject to additional funding.
Liquidity outlook indicated operations funded into Q3 2026; cash and cash equivalents totaled USD 21 million as of Dec. 31, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sangamo Therapeutics Inc. published the original content used to generate this news brief on March 30, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623329393?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 04:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623329393","market":"fut","top_or_hot":-1,"title":"Sangamo publishes corporate presentation highlighting neurology genomic medicines pipeline, Fabry BLA progress","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sangamo publishes corporate presentation highlighting neurology genomic medicines pipeline, Fabry BLA progress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Sangamo repositioned strategy around neurology-focused genomic medicines built on zinc-finger epigenetic regulation cargo, supported by STAC-BBB CNS delivery platform.\n        </li>\n<li>\n          Chronic neuropathic pain candidate ST-503 entered Phase 1/2 STAND study in small fiber neuropathy; U.S. FDA granted <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> designation.\n        </li>\n<li>\n          Prion disease program ST-506 advanced CTA-enabling work; GLP toxicology study completed with analysis ongoing.\n        </li>\n<li>\n          Fabry gene therapy ST-920 moved through rolling BLA submission under Accelerated Approval; completion targeted as early as summer 2026 subject to additional funding.\n        </li>\n<li>\n          <a href=\"https://laohu8.com/S/LQDT\">Liquidity</a> outlook indicated operations funded into Q3 2026; cash and cash equivalents totaled USD 21 million as of Dec. 31, 2025.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/SGMO\">Sangamo Therapeutics Inc</a>. published the original content used to generate this news brief on March 30, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sangamo publishes corporate presentation highlighting neurology genomic medicines pipeline, Fabry BLA progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSangamo publishes corporate presentation highlighting neurology genomic medicines pipeline, Fabry BLA progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-31 04:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sangamo publishes corporate presentation highlighting neurology genomic medicines pipeline, Fabry BLA progress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Sangamo repositioned strategy around neurology-focused genomic medicines built on zinc-finger epigenetic regulation cargo, supported by STAC-BBB CNS delivery platform.\n        </li>\n<li>\n          Chronic neuropathic pain candidate ST-503 entered Phase 1/2 STAND study in small fiber neuropathy; U.S. FDA granted <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> designation.\n        </li>\n<li>\n          Prion disease program ST-506 advanced CTA-enabling work; GLP toxicology study completed with analysis ongoing.\n        </li>\n<li>\n          Fabry gene therapy ST-920 moved through rolling BLA submission under Accelerated Approval; completion targeted as early as summer 2026 subject to additional funding.\n        </li>\n<li>\n          <a href=\"https://laohu8.com/S/LQDT\">Liquidity</a> outlook indicated operations funded into Q3 2026; cash and cash equivalents totaled USD 21 million as of Dec. 31, 2025.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/SGMO\">Sangamo Therapeutics Inc</a>. published the original content used to generate this news brief on March 30, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL4B6zMY:1","article_id":"2623329393","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623329393","pubTimestamp":1774901594,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sangamo repositioned strategy around neurology-focused genomic medicines built on zinc-finger epigenetic regulation cargo, supported by STAC-BBB CNS delivery platform.Chronic neuropathic pain candidate ST-503 entered Phase 1/2 STAND study in small fiber neuropathy; U.S. FDA granted Fast Track designation.Prion disease program ST-506 advanced CTA-enabling work; GLP toxicology study completed with analysis ongoing.Fabry gene therapy ST-920 moved through rolling BLA submission under Accelerated Approval; completion targeted as early as summer 2026 subject to additional funding.Liquidity outlook indicated operations funded into Q3 2026; cash and cash equivalents totaled USD 21 million as of Dec. 31, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or l","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4556":"基因编辑","SGMO":"Sangamo Therapeutics Inc"},"translate_title":"Sangamo发布公司演示文稿，重点介绍神经病学基因组药物管道、Fabry BLA进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SGMO":0.9},"content_text":"Sangamo publishes corporate presentation highlighting neurology genomic medicines pipeline, Fabry BLA progress\n    \n\n\n          Sangamo repositioned strategy around neurology-focused genomic medicines built on zinc-finger epigenetic regulation cargo, supported by STAC-BBB CNS delivery platform.\n        \n\n          Chronic neuropathic pain candidate ST-503 entered Phase 1/2 STAND study in small fiber neuropathy; U.S. FDA granted Fast Track designation.\n        \n\n          Prion disease program ST-506 advanced CTA-enabling work; GLP toxicology study completed with analysis ongoing.\n        \n\n          Fabry gene therapy ST-920 moved through rolling BLA submission under Accelerated Approval; completion targeted as early as summer 2026 subject to additional funding.\n        \n\nLiquidity outlook indicated operations funded into Q3 2026; cash and cash equivalents totaled USD 21 million as of Dec. 31, 2025.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sangamo Therapeutics Inc. published the original content used to generate this news brief on March 30, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623329393","isCrawlerRequest":true}